D. Boral Capital Lowers Quince Therapeutics (NASDAQ:QNCX) Price Target to $4.00

Quince Therapeutics (NASDAQ:QNCX) had its target price cut by D. Boral Capital from $12.00 to $4.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Other analysts also recently issued research reports about the company. Brookline Capital Management initiated coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 target price on the stock. Oppenheimer began coverage on Quince Therapeutics in a research note on Monday. They set an “outperform” rating and a $10.00 price objective on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $8.00.

Quince Therapeutics Price Performance

NASDAQ QNCX opened at $1.37 on Tuesday. The firm’s 50 day moving average is $1.49 and its 200-day moving average is $1.44. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $60.28 million, a PE ratio of -1.10 and a beta of 0.71. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. Equities research analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Anfield Capital Management LLC acquired a new stake in shares of Quince Therapeutics in the fourth quarter valued at approximately $50,000. Virtu Financial LLC bought a new stake in Quince Therapeutics in the 4th quarter valued at $55,000. Two Sigma Investments LP acquired a new stake in Quince Therapeutics during the 4th quarter valued at $57,000. Northern Trust Corp boosted its position in Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after purchasing an additional 16,501 shares during the period. Finally, Scharf Investments LLC acquired a new position in shares of Quince Therapeutics in the fourth quarter valued at $170,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.